PMC10185749_01
MRI T2W and stir-weighted images of the muscles at the time of onset. (A,D) T2W and Stir images at the time of onset, showing a high signal on T2-weighted and Stir images. (B,E) T2W and Stir images at the time of recurrence, showing extensive muscle damage. (C,F) T2W and Stir images one year after the application of Adalimumab.
fped-11-1149785-g001.jpg
PMC10185749_01_fped-11-1149785-g001.jpg
F1
Magnetic resonance imaging (MRI) showed high signals on T2-weighted and Stir images of the legs and no rhabdomyolysis or muscle necrosis, as shown in Figures 1A,D. T2-weighted and Stir images (Figures 1B,E). MP dosage was adjusted to 32 mg/day, and 40 mg adalimumab was subcutaneously injected every two weeks. The muscle strength of her limbs improved. MRI T2W and Stir-weighted images of the legs revealed decreased muscle damage one year after relapse (Figures 1C,F).